Tyra Biosciences(TYRA) - 2024 Q1 - Quarterly Results

CARLSBAD, Calif., May 9, 2024 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended March 31, 2024, and highlighted recent corporate progress. Exhibit 99.1 Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights - TYRA-300 on track in ACH and oncology; SURF301 Ph1 in ...